Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector

Thomas J. Conlon, Glenn Walter, Renius Owen, Travis Cossette, Kirsten Erger, Greg Gutierrez, Eric Goetzman, Dietrich Matern, Jerry Vockley, Terence R. Flotte

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mitochondrial β-oxidation of fatty acids is required to meet physiologic energy requirements during illness and periods of fasting or physiologic stress, and is most active in liver and striated muscle. Acyl-CoA dehydrogenases of varying chain-length specificities represent the first step in the mitochondria for each round of β-oxidation, each of which removes two-carbon units as acetyl-CoA for entry into the tricarboxylic acid cycle. We have used recombinant adeno-associated virus (rAAV) vectors expressing short-chain acyl-CoA dehydrogenase (SCAD) to correct the accumulation of fatty acyl-CoA intermediates in deficient cell lines. The rAAV-SCAD vector was then packaged into either rAAV serotype 1 or 2 capsids and injected intramuscularly into SCAD-deficient mice. A systemic effect was observed as judged by restoration of circulating butyryl-carnitine levels to normal. Total lipid content at the injection site was also decreased as demonstrated by noninvasive magnetic resonance spectroscopy (MRS). SCAD enzyme activity in the injected muscle was found at necropsy to be above the normal control mouse level. This study is the first to demonstrate the systemic correction of a fatty acid oxidation disorder with rAAV and the utility of MRS as a noninvasive method to monitor SCAD correction after in vivo gene therapy.

Original languageEnglish (US)
Pages (from-to)71-80
Number of pages10
JournalHuman Gene Therapy
Volume17
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Butyryl-CoA Dehydrogenase
Dependovirus
Intramuscular Injections
Fatty Acids
Acyl-CoA Dehydrogenases
Magnetic Resonance Spectroscopy
Acyl Coenzyme A
Acetyl Coenzyme A
Citric Acid Cycle
Striated Muscle
Carnitine
Capsid
Genetic Therapy
Fasting
Mitochondria
Carbon
Lipids
Cell Line
Muscles
Injections

ASJC Scopus subject areas

  • Genetics

Cite this

Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector. / Conlon, Thomas J.; Walter, Glenn; Owen, Renius; Cossette, Travis; Erger, Kirsten; Gutierrez, Greg; Goetzman, Eric; Matern, Dietrich; Vockley, Jerry; Flotte, Terence R.

In: Human Gene Therapy, Vol. 17, No. 1, 01.2006, p. 71-80.

Research output: Contribution to journalArticle

Conlon, TJ, Walter, G, Owen, R, Cossette, T, Erger, K, Gutierrez, G, Goetzman, E, Matern, D, Vockley, J & Flotte, TR 2006, 'Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector', Human Gene Therapy, vol. 17, no. 1, pp. 71-80. https://doi.org/10.1089/hum.2006.17.71
Conlon, Thomas J. ; Walter, Glenn ; Owen, Renius ; Cossette, Travis ; Erger, Kirsten ; Gutierrez, Greg ; Goetzman, Eric ; Matern, Dietrich ; Vockley, Jerry ; Flotte, Terence R. / Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector. In: Human Gene Therapy. 2006 ; Vol. 17, No. 1. pp. 71-80.
@article{80a9043c66b6420ca73c2d07691b6d10,
title = "Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector",
abstract = "Mitochondrial β-oxidation of fatty acids is required to meet physiologic energy requirements during illness and periods of fasting or physiologic stress, and is most active in liver and striated muscle. Acyl-CoA dehydrogenases of varying chain-length specificities represent the first step in the mitochondria for each round of β-oxidation, each of which removes two-carbon units as acetyl-CoA for entry into the tricarboxylic acid cycle. We have used recombinant adeno-associated virus (rAAV) vectors expressing short-chain acyl-CoA dehydrogenase (SCAD) to correct the accumulation of fatty acyl-CoA intermediates in deficient cell lines. The rAAV-SCAD vector was then packaged into either rAAV serotype 1 or 2 capsids and injected intramuscularly into SCAD-deficient mice. A systemic effect was observed as judged by restoration of circulating butyryl-carnitine levels to normal. Total lipid content at the injection site was also decreased as demonstrated by noninvasive magnetic resonance spectroscopy (MRS). SCAD enzyme activity in the injected muscle was found at necropsy to be above the normal control mouse level. This study is the first to demonstrate the systemic correction of a fatty acid oxidation disorder with rAAV and the utility of MRS as a noninvasive method to monitor SCAD correction after in vivo gene therapy.",
author = "Conlon, {Thomas J.} and Glenn Walter and Renius Owen and Travis Cossette and Kirsten Erger and Greg Gutierrez and Eric Goetzman and Dietrich Matern and Jerry Vockley and Flotte, {Terence R.}",
year = "2006",
month = "1",
doi = "10.1089/hum.2006.17.71",
language = "English (US)",
volume = "17",
pages = "71--80",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector

AU - Conlon, Thomas J.

AU - Walter, Glenn

AU - Owen, Renius

AU - Cossette, Travis

AU - Erger, Kirsten

AU - Gutierrez, Greg

AU - Goetzman, Eric

AU - Matern, Dietrich

AU - Vockley, Jerry

AU - Flotte, Terence R.

PY - 2006/1

Y1 - 2006/1

N2 - Mitochondrial β-oxidation of fatty acids is required to meet physiologic energy requirements during illness and periods of fasting or physiologic stress, and is most active in liver and striated muscle. Acyl-CoA dehydrogenases of varying chain-length specificities represent the first step in the mitochondria for each round of β-oxidation, each of which removes two-carbon units as acetyl-CoA for entry into the tricarboxylic acid cycle. We have used recombinant adeno-associated virus (rAAV) vectors expressing short-chain acyl-CoA dehydrogenase (SCAD) to correct the accumulation of fatty acyl-CoA intermediates in deficient cell lines. The rAAV-SCAD vector was then packaged into either rAAV serotype 1 or 2 capsids and injected intramuscularly into SCAD-deficient mice. A systemic effect was observed as judged by restoration of circulating butyryl-carnitine levels to normal. Total lipid content at the injection site was also decreased as demonstrated by noninvasive magnetic resonance spectroscopy (MRS). SCAD enzyme activity in the injected muscle was found at necropsy to be above the normal control mouse level. This study is the first to demonstrate the systemic correction of a fatty acid oxidation disorder with rAAV and the utility of MRS as a noninvasive method to monitor SCAD correction after in vivo gene therapy.

AB - Mitochondrial β-oxidation of fatty acids is required to meet physiologic energy requirements during illness and periods of fasting or physiologic stress, and is most active in liver and striated muscle. Acyl-CoA dehydrogenases of varying chain-length specificities represent the first step in the mitochondria for each round of β-oxidation, each of which removes two-carbon units as acetyl-CoA for entry into the tricarboxylic acid cycle. We have used recombinant adeno-associated virus (rAAV) vectors expressing short-chain acyl-CoA dehydrogenase (SCAD) to correct the accumulation of fatty acyl-CoA intermediates in deficient cell lines. The rAAV-SCAD vector was then packaged into either rAAV serotype 1 or 2 capsids and injected intramuscularly into SCAD-deficient mice. A systemic effect was observed as judged by restoration of circulating butyryl-carnitine levels to normal. Total lipid content at the injection site was also decreased as demonstrated by noninvasive magnetic resonance spectroscopy (MRS). SCAD enzyme activity in the injected muscle was found at necropsy to be above the normal control mouse level. This study is the first to demonstrate the systemic correction of a fatty acid oxidation disorder with rAAV and the utility of MRS as a noninvasive method to monitor SCAD correction after in vivo gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=30744432678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744432678&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.71

DO - 10.1089/hum.2006.17.71

M3 - Article

VL - 17

SP - 71

EP - 80

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -